Evommune, Inc. (EVMN) Stock Ticker
EVMN right now
Market factors today
Unlock the full EVMN picture
About Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
EVMN stock facts
| Ticker symbol | EVMN |
| Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $308.1M |
| CEO | Luis C. Pena |
| Employees | 48 |
| Headquarters | Palo Alto, CA, US |
| IPO date | 2025-11-06 |
| Website | www.evommune.com |
What you can see for EVMN on Tickr
Live EVMN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the EVMN report.
Rankings
FAQ
What is the ticker symbol for Evommune, Inc.?
The ticker symbol for Evommune, Inc. is EVMN, listed on the New York Stock Exchange.
What is EVMN?
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's…